araag2/HINT huggingface dataset:
Clinical trial NCT00304551 (phase 3, status: completed)
Conditions: liver cirrhosis, chronic hepatitis c
ICD codes: K74.60, K74.69, P78.81, K71.7, K70.30, K70.31, B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: peginterferon alfa-2a 180μg, peginterferon alfa-2a 90μg, ribavirin
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients aged 20 to 75 years-old with quantifiable serum HCV-RNA (≥ 500 IU/mL),
             elevated serum alanine aminotransferase activity (≥ 45 IU per liter) within sixty days
             of screening, and proven CHC with compensated LC (Child-Pugh A) on liver biopsy.

        Exclusion Criteria:

          -  Patients with neutropenia (fewer than 1,500 neutrophils per cubic millimeter)

          -  Thrombocytopenia (fewer than 75,000 platelets per cubic millimeter)

          -  Anemia (less than 12 g hemoglobin per deciliter )

          -  Hepatitis B co-infection; decompensated liver disease.

          -  Organ transplant

          -  Creatinine clearance less than 50 milliliters per minute

          -  Poorly controlled psychiatric disease

          -  Poorly controlled diabetes

          -  Malignant neoplastic disease

          -  Severe cardiac or chronic pulmonary disease

          -  Immunologically mediated disease

          -  Retinopathy
Clinical trial NCT00433420 (phase 3, status: active, not recruiting)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: cyclophosphamide, epirubicin hydrochloride, fluorouracil, paclitaxel
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary breast cancer

               -  No histology other than carcinoma

          -  Node-positive disease

               -  Must have at least 1 involved axillary node or internal mammary node

          -  Previously resected disease

               -  Has undergone radical surgery (i.e., mastectomy or conservative surgery) with
                  axillary node dissection within the past 7 weeks

          -  No inflammatory carcinoma

          -  No prior or concurrent ipsilateral or contralateral invasive breast carcinoma

          -  No metastatic disease, including metastasis in the ipsilateral supraclavicular lymph
             nodes

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Female

          -  Menopausal status not specified

          -  ECOG performance status 0-1

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  WBC ≥ 4,000/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 9 g/dL

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  Creatinine ≤ 1.5 times ULN

          -  AST and ALT ≤ 2.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No chronic liver or renal disease

          -  No other serious medical illness requiring medication

          -  No other malignancy except adequately treated, cone-biopsied in situ carcinoma of the
             cervix or basal cell or squamous cell carcinoma of the skin

          -  No symptomatic peripheral neuropathy > grade 2

          -  No hypersensitivity to study drugs or their components

          -  No recent myocardial infarction, congestive heart failure, or serious arrhythmia

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior chemotherapy

          -  No prior cytotoxic regimens

          -  No prior radiation therapy, except for intraoperative radiation therapy
Clinical trial NCT00090025 (phase 3, status: terminated)
Conditions: biliary tract cancer
ICD codes: C24.9, C24.8
Drugs: becatecarin, 5-fluorouracil plus leucovorin
SMILES: CCN(CC)CCN1C(=O)C2=C(C1=O)C1=C(N([C@@H]3O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]3O)C3=C(Cl)C=CC=C13)C1=C2C2=C(N1)C(Cl)=CC=C2, FC1=CNC(=O)NC1=O
Reason stopped: 
    futility reasons after independent data monitoring committee interim analysis
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female subjects with advanced histologically confirmed biliary cancer
             (gallbladder cancer or cholangiocarcinoma) that is not amenable to conventional
             surgical approach

          -  18 years or older

          -  Life expectancy of at least 12 weeks

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status score less than 3

          -  Willing and able to sign informed consent

          -  Sexually active men and women must use an accepted and effective method of
             contraception (including barrier contraception with spermicide)

          -  Women of child-bearing age must have a negative pregnancy test

          -  Laboratory criteria

        Exclusion Criteria:

          -  Prior chemotherapy (excluding chemotherapy given as adjuvant treatment completing more
             than 6 months prior to entry into study)

          -  Unstable angina, or class III or IV New York Heart Association heart disease

          -  Central nervous system metastases

          -  Uncontrolled diabetes mellitus

          -  Uncontrolled seizure disorder

          -  Major surgery, chemotherapy, immunotherapy, or radiotherapy during the 28 days
             preceding the first study treatment

          -  Need for concomitant anticancer therapy (chemotherapy, immunotherapy, or radiation) or
             other investigational agents during study participation or 28 days prior to study
             participation

          -  Pregnant or breast-feeding

          -  A known history of human immunodeficiency virus (HIV) infection
Clinical trial NCT01031680 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus, cardiovascular disease, hypertension, inadequate glycaemic control
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, A52.00, A52.09, A50.54, Z01.810, Q87.418, Z13.6, R94.30, I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10, Z59.1, O62.0, Z72.821, Z58.6, Z62.0, Z73.4
Drugs: dapagliflozin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus.

          -  Cardiovascular disease

          -  Hypertension

        Exclusion Criteria:

          -  Patients with type 1 diabetes or diabetes insipidus

          -  Patients with 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or
             poorly controlled diabetes

          -  Any clinically significant illness, which would compromise the patient's safety and
             their participation in the study
Clinical trial NCT00509236 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2, end-stage kidney disease
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, I12.0, I13.11, I13.2
Drugs: sitagliptin, glipizide
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Participant has T2DM.

          -  Participant is on dialysis on day of signing informed consent.

          -  Participant is unlikely to conceive or uses acceptable methods of birth control:
             hormonal contraceptive, intrauterine device (IUD), diaphragm with spermicide,
             contraceptive sponge, condom, or vasectomy.

          -  Participant has hemoglobin A1c ≥7% and ≤9% measured at or within 2 weeks prior to
             Visit 4/Week -2.

          -  Participant is ≥85% compliant with study medication during the single-blind placebo
             run-in (as determined by tablet/capsule count) and compliant with diet, exercise and
             other run-in treatments during the run-in period.

        Exclusion Criteria:

          -  Participant has a history of type 1 diabetes mellitus or a history of ketoacidosis.

          -  Participant is losing weight in a weight loss program and is not in the maintenance
             phase (defined as <2 kg weight loss in 2 months), or intends to be involved in weight
             loss intervention outside that prescribed by the study.

          -  Participant has a clinically significant hematological disorder (e.g., aplastic
             anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia).

          -  Participant has cirrhosis or active liver disease.

          -  Participant has been on dialysis for < 6 months.

          -  Participant has been diagnosed with a significant cardiovascular disorder and has new
             or worsening signs or symptoms of congestive heart failure within 3 months of signing
             informed consent.

          -  Participant has severe active peripheral vascular disease.

          -  Participant has a history of malignancy ≤ 5 years prior to signing informed consent,
             or > 5 years without documentation of remission/cure.

          -  Participant is under treatment for hyperthyroidism.

          -  Participant has a hypersensitivity or contraindication to glipizide.
Clinical trial NCT00147199 (phase 3, status: completed)
Conditions: pulmonary hypertension
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: inhaled treprostinil, placebo inhalation solution
SMILES: [H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinically stable, pulmonary arterial hypertension diagnosed as either idiopathic or
             familial PAH, collagen vascular disease associated PAH, HIV PAH, or PAH induced by
             anorexigens, New York Heart Association (NYHA) Class III or Class IV.

          -  Been on a stable dose of 125 mg twice daily (bid) of bosentan OR any stable dose of
             sildenafil for at least three months prior to study start

          -  An unencouraged six minute walk test (6MWT) of between 200 and 450 meters at screening

          -  Cardiac catheterization within the past 13 months consistent with PAH, specifically
             mean pulmonary artery pressure (PAPm) ≥25 mmHg (at rest), pulmonary capillary wedge
             pressure (PCWP) (or left ventricular end diastolic pressure) ≤15 mmHg, and pulmonary
             vascular resistance (PVR) >3 mmHg/L/min

          -  Within the past 12 months, patients must have had a chest radiograph consistent with
             the diagnosis of PAH

          -  Willing and able to follow all study procedures

        Exclusion Criteria:

          -  Considering pregnancy, are pregnant and/or lactating

          -  PAH due to conditions other than noted in the above inclusion criteria.

          -  Have had any change in or discontinued any PAH medication within the last three
             months, including but not limited to endothelin receptor antagonist (ERA), or calcium
             channel blockers (CCB) (with the exception of anticoagulants)

          -  Have received any prostanoid within the 30 days before screening or are scheduled to
             receive any during the course of the study

          -  Have received any investigational medication within 30 days prior to the start of this
             study or are scheduled to receive another investigational drug during the course of
             this study

          -  Have a known intolerance to any drug, especially to treprostinil sodium or prostanoids

          -  Have an increased risk of hemorrhage

          -  Have a new type of chronic therapy (e.g., a different category of vasodilator,
             diuretic) for PAH added within the last month, except anticoagulants

          -  Have any musculoskeletal disease or any other disease that would limit ambulation.
Clinical trial NCT00245505 (phase 3, status: terminated)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: mesalazine (mesalamine)
SMILES: NC1=CC(C(O)=O)=C(O)C=C1
Reason stopped: 
    study terminated due to lack of eligible patients
  
Eligibility criteria:

        4.2 Inclusion Criteria

          1. Patients who have signed the informed consent form

          2. Patients with performed complete VCE < 7 days prior to inclusion and diagnosed
             clinically active mild to moderate small bowel CD and no stricture on previous
             examinations, as previously proven by barium small bowel follow through, enteroclysis
             and / or patency test capsule.

          3. Patients between 18 - 70 years of age.

        4.3 Exclusion Criteria

          1. Patients with evidence of other forms of inflammatory small bowel bowel disease,
             idiopathic proctitis or infectious disease.

          2. Patients with known small bowel strictures from previous examinations with for
             instance barium small bowel follow through, enteroclysis and / or patency capsule
             test.

          3. Patients with pacemaker due to lack of VCE interaction data.

          4. Patients who cannot undergo study procedures due to swallowing disorders.

          5. Planned or actual pregnancy or lactation.

          6. Women of child-bearing potential who are not using an effective method of
             contraception, in the opinion of the investigator.

        8. Patients receiving maintenance treatment (p.o.) with total daily doses above 2.0g of
        sulphasalazine, mesalazine or 4-ASA, for 30 days prior to entry into the study.

        9. Chronic use of non-steroidal anti-inflammatory drugs (oral and/or rectal routes) in 30
        days prior to inclusion in the study (chronic use is defined as drug intake for a minimum
        of 3 consecutive days).

        10. Intake of corticosteroids (oral and/or rectal routes) within the 30 days prior to
        enrolment in the study.

        11. Patients receiving any immunosuppressive (azathioprine, 6-MP, etc) agents during 30
        days prior to study enrolment.

        12. Patients receiving any Crohn specific biological agents (TNF-alfa) during the last year
        prior to study enrolment.

        13. Patients with any other disease or condition which may interfere with study assessments
        as judged by the investigator.

        14. Alcoholism or drug addiction. 15. Patients participating or having participated in
        another clinical study in the previous 30 days.

        16. Patients with severe renal/hepatic impairment (see section 5.6) as judged by the
        investigator.

        17. Patients who are allergic to salicylate or 5-ASA derivatives. 18. Patients who are
        unlikely to comply with the protocol. 19. Any patient who has previously taken part in this
        study. 20. Patients who are unable to write or read local language
Clinical trial NCT00601367 (phase 3, status: completed)
Conditions: sexual dysfunctions, psychological
ICD codes: O9A.52, F88, F89, O9A.53, T74.31XS, T74.32XS, T76.31XS
Drugs: flibanserin flexible dose
SMILES: FC(F)(F)C1=CC(=CC=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Women with a primary diagnosis of HSDD who still needs to be treated according to the
             investigator's opinion and willing to continue in this study. This continuation
             requires adequate compliance, in the Investigators judgement, with trial medication
             and the trial visit required in the parent clinical trial (Visit 1 to visit 9).

          -  Patients must have used a medically acceptable method of contraception [i.e., double
             barrier method (e.g., diaphragm or condom and spermicide), hormonal therapy
             (subcutaneous, injectable, intra-vaginal, or oral contraceptive), intrauterine device,
             tubal sterilization, or partner's surgical sterilization] for at least 3 months before
             the Screen Visit and continue to use that medically acceptable method of contraception
             during the trial.

        Exclusion Criteria:

          -  Patients with a history of MDD within 6 months prior the Screen Visit or a score of 14
             on the Beck Depression Inventory II, or a history of suicide attempt according to the
             Beck Scale for Suicide Ideation, or patient with any non-zero statement in the first
             five items for the Beck Scale for Suicide Ideation.

          -  Patients must have a clinically acceptable Pap smear as read by a cytology facility
             (no evidence of malignancy or squamous intraepithelial lesions) within 6 months before
             the Inclusion Visit.

          -  Patients with findings at the Screen Visit of pelvic inflammatory disease, urinary
             tract or vaginal infection/vaginitis, cervicitis, interstitial cystitis, vulvodynia,
             or significant vaginal atrophy.

          -  Patients experiencing major life stress (including parenting pressure, eldercare, loss
             of income, death of a family member, etc.) or relationship discord that could
             interfere with sexual activity, except distress about HSDD.

          -  Clinically significant ECG abnormalities at the Screen Visit, according to the
             investigators opinion or the cardiologist who have performed the ECG. The following
             ECG values are considered to be exclusionary: QTc intervals >480 milliseconds (ms), PR
             intervals >240 ms, and QRS intervals >110 ms.
Clinical trial NCT00383019 (phase 3, status: completed)
Conditions: glaucoma, primary open angle (poag), ocular hypertension
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821, H40.053, H40.051, H40.052, H40.059
Drugs: xalacom (kp2035), xalatan
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Intraocular pressure is 18 mmHg or more at baseline after treatment with Xalatan for 4
             weeks or more.

        Exclusion Criteria:

          -  History of no-response to timolol

          -  History of trabeculectomy

          -  History of other ocular surgery including ALT, SLT,and trabeculotomy within 6 months
Clinical trial NCT00195676 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: adalimumab
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject was age 18 or older and in good health (Investigator discretion) with a recent
             stable medical history.

          -  Subjects who met the requirements from previous adalimumab psoriasis study
             participation.

        Exclusion Criteria:

          -  Subject considered by the Investigator, for any reason, to be an unsuitable candidate
             for the study.

          -  Female subject who was pregnant or breast-feeding or considering becoming pregnant.
Clinical trial NCT00506415 (phase 3, status: completed)
Conditions: alzheimer disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: rivastigmine 5 cm^2, rivastigmine 10 cm^2, rivastigmine 15 cm^2, placebo to 15 cm^2 patch, placebo to 10 cm^2 patch
SMILES: CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C, CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C, CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients between 50 and 85 years of age with a diagnosis of probable
             Alzheimers Disease,

          -  Baseline Mini-Mental State Examination (MMSE) score 10-24 inclusive,

          -  A primary caregiver willing to accept responsibility for supervising treatment,
             assessing the patient's condition throughout the study, and for providing input into
             efficacy assessments.

          -  For double blind only: Meet the decline criteria of functional (as assessed by the
             investigator) and cognitive (assessed by a 1 point reduction in Mini-Mental State
             Examination) score between visits or a 3 point reduction from baseline) decline at
             weeks 23, 36 or 48.

        Exclusion Criteria:

          -  Presence of an advanced, severe, progressive, or unstable disease of any type that
             could interfere with efficacy and safety assessments or put the patient at particular
             risk,

          -  Any medical or neurological condition other than Alzheimers Disease that could explain
             the patient's dementia,

          -  A diagnosis of probable or possible vascular dementia,

          -  A current diagnosis of unsuccessfully-treated depression, or any other mental disorder
             that may interfere with the evaluation of the patient's response to study medication,

          -  A history or current diagnosis of cerebrovascular disease (e.g. stroke),

          -  A current diagnosis of severe or unstable cardiovascular disease (e.g. unstable
             coronary artery disease).

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00003317 (phase 3, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin, paclitaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed stage IIIA non-small cell lung cancer
        that has been completely resected by lobectomy, bilobectomy, pneumonectomy, or sleeve
        lobectomy through any incision (thoracoscopic or video assisted resection is acceptable) No
        known residual disease present Involvement in N2 nodes must have been determined only at
        the time of surgical exploration or by postoperative pathologic diagnosis All grossly
        involved nodes must be removed at surgery No positive mediastinoscopy (if lymph nodes on CT
        scan are greater than 1.5 cm in diameter, mediastinoscopy is required)

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ZUBROD 0-1 Life expectancy:
        Not specified Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least
        100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL SGOT no greater than upper limit of
        normal Renal: Creatinine clearance at least 20 mL/min Other: Not pregnant or nursing

        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent growth factors Chemotherapy: No
        prior chemotherapy for non-small cell lung cancer No other concurrent chemotherapy
        Endocrine therapy: No concurrent hormone therapy except: Steroids for adrenal failure
        Hormones for nondisease related conditions Dexamethasone as an antiemetic Radiation
        therapy: No prior radiotherapy for non-small cell lung cancer Surgery: See Disease
        Characteristics